Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

Memorial Sloan Kettering Cancer Center (MSK)

Status: Terminated

Conditions: Penile Cancer; Erectile Dysfunction; Radical Prostatectomy

Treatments: Drug: Placebo QHS and sildenafil and questionnaires; Drug: Sildenafil and questionnaire; Drug: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00955929

09-005 (Other Identifier)

Details and patient eligibility

About

When a bilateral nerve-sparing radical prostatectomy (RP) is performed, recovery of erectile function (rigid erections) is reported for up to 80% of patients, who are less than 60 years old. Erectile function recovery is also impacted by patient age, erectile function before surgery, and the length of time after surgery.

Current evidence from studies suggests that developing erections is important, however, these studies have been small, and the evidence is not definite. Animal studies suggest that erection medication (Viagra, Levitra, Cialis) may protect erection tissue, even in the absence of erections. However, the correct treatment plan is unknown. For example, how often does a man need to take sildenafil (Viagra®) to protect his erectile function or to maximize his erectile function recovery? Is only using erection medication enough for erectile function recovery? Would penile injections, which almost ensure production of an erection, be better than using sildenafil (Viagra®), or might a combination be even better at helping recovery of erections? These are types of questions this study might answer.

Enrollment: 76 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male, must be ≥ 18 years of age, with histologically confirmed prostate adenocarcinoma, that is clinically localized to the prostate gland
• Stable sexual relationship for ≥ 6 months
• Open or laparoscopic bilateral nerve-sparing radical prostatectomy
• Baseline score of ≥ 22 on the International Index of Erectile Function Domain (Appendix A)
• Able to speak, read and write in the English language
• Calculated creatinine clearance using the 4 variable MDRD equation based on serum creatinine, age, race, and gender of > 60 cc/min
• Patient is able to walk up two flights of stairs briskly without chest pain
• Patient needs to have their baseline sitting AND standing blood pressure and pulse done at the time of consent

Exclusion criteria

• Preoperative or planned postoperative pelvic radiation therapy

• Preoperative or planned postoperative androgen deprivation

• Presence of Peyronie's disease at baseline

• Presence of a penile prosthesis at baseline

• Resection of one or both nerve bundles at surgery

• Any contraindications to sildenafil:

  • Patient is currently using nitrates;
  • Presence of retinitis pigmentosa;
  • Presence macular degeneration;
  • MI or CVA within 3 months;
  • Patient is currently using MAOI medications

• Patient is currently using penile self injection medication (Trimix, Bimix, or PGE-1)

• Patient requiring sildenafil for penetration

• Use of sildenafil within 30 days of consent

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

76 participants in 3 patient groups

PRN Sildenafil

Experimental group

Description:

Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.

Treatment:

Drug: Placebo QHS and sildenafil and questionnaires

Nightly Sildenafil Arm

Experimental group

Description:

Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.

Treatment:

Drug: Sildenafil and questionnaire

Combination Therapy Arm

Experimental group

Description:

Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).

Treatment:

Drug: Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires